<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1573">
  <stage>Registered</stage>
  <submitdate>23/12/2003</submitdate>
  <approvaldate>23/12/2003</approvaldate>
  <actrnumber>ACTRN12607000063415</actrnumber>
  <trial_identification>
    <studytitle>Immediate or delayed radiotherapy after surgery for melanoma involving lymph nodes</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 02.01 - A randomised clinical trial of surgery versus surgery plus adjuvant radiotherapy in patients with completely resected macroscopic nodal metastatic melanoma to improve regional relapse rates.</scientifictitle>
    <utrn />
    <trialacronym>TROG 02.01</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT00287196</secondaryid>
    <secondaryid>National Clinical Trials Registry: NCTR487</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic melanoma</healthcondition>
    <healthcondition>Lymph node disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>ARM 1: Immediate Post-operative radiotherapy. 48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days</interventions>
    <comparator>ARM 2: Observation with delayed radiotherapy for relapse. Dose is at treating physician discretion.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of regional relapse - Time to regional failure.</outcome>
      <timepoint>Measured until death. Follow up visits are every 3 months from randomisation for the first 2 years, then every 6 months until 5 years and then annually.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Failure free survival</outcome>
      <timepoint>Measured from the date of randomisation to the date of a relapse in any site or death. Follow up visits are every 3 months from randomisation for the first 2 years, then every 6 months until 5 years and then annually. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Measured from date of randomisation to the date of death from any cause. Follow up visits are every 3 months from randomisation for the first 2 years, then every 6 months until 5 years and then annually. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint>2 and 6 weeks post radiotherapy, every 3 months from randomisation for first 2 years, then every 6 months until 5 years and then annually until relapse or death. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life</outcome>
      <timepoint>Pre-randomisation and then every 3 months from randomisation for first 2 years, then every 6 months until 5 years and then annually until relapse or death.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All of the following criteria must apply for the patient to be eligible for the trial:
1. Regional macroscopic (palpable) nodal metastatic melanoma in one nodal basin region only (either parotid/neck, axilla or groin) which has been completely resected.
Patients presenting according to any of the three following ways are eligible: node metastases (i) occurring concurrently with the initial diagnosis of primary melanoma, (ii) appearing subsequently after the successful treatment of the primary, or (iii) as a first presentation of melanoma with an unknown primary.
Patients who undergo two or more operations to achieve total standards specified for lymphadenectomy must complete them within 8 weeks. A previous biopsy (open or closed) where the operative intent was not a definitive curative procedure does not need to be included within this 8 week period. Patients who undergo a procedure that is not curative in intent (e.g. revision of wound edges) after a definitive procedure that is curative in intent (e.g. inguinal
lymphadenectomy) will need to have this procedure completed within 12 weeks following the final definitive procedure.
2. A completed Synoptic Pathology Report which states that:
(a) resection is complete
And
(b) the lymphadenectomy specimen contains the required minimum numbers of
harvested nodes in the involved sites, as follows:
Superficial parotidectomy 2
Neck dissection
Comprehensive (levels I-V) 25
Selective
   4 levels (e.g. Sentinal Node Dissection (SND) (I-IV) or Sentinal Node Dissection (SND) (II-V, +/-postauricular/occipital) 20
  3 levels (e.g. Sentinal Node Dissection (SND) (I-III) or Sentinal Node Dissection (SND) (III-V)
15
Axillary dissection 10
Superficial inguinal dissection (4 for deep inguinal/pelvic node dissection if
performed in conjunction with superficial inguinal dissection) 6
3. At significant risk of regional relapse, defined as at least one of the following being present (as per Synoptic Pathology Report):
a) the number of nodes involved is:
&gt; 1 node for parotid, or
&gt; 2 nodes for neck or axilla, or
&gt; 3 nodes for groin.
or b) Extranodal tissue spread;
or c) Any one metastatic node of maximum diameter = 3 cm neck, or = 4 cm in axilla or groin.
4. All staging investigations have been completed: Computed Tomography (CT) of nodal basin, Computed Tomography of
chest/abdomen/pelvis and Computed Tomography of brain. (Brain Magnetic Resonance Imaging may be substituted for brain Computed Tomography for initial staging only.)
5. Serum Lactate Dehydrogenase (LDH) &lt; 1.5 times the upper limit of normal.
6. World Health Organisation (WHO) performance status of 0 or 1.
7. Age 18 years or older.
8. Expected life span of two or more years in the absence of melanoma.
9. A photograph has been taken of the involved nodal basin region; the photograph is to include the recent lymphadenectomy scar(s) and the defined anatomic boundaries drawn on the skin
for the node basin region concerned (refer to section 8.2 for details).
10. Radiotherapy must be able to be commenced within 12 weeks of lymphadenectomy.
11. Patient must not be pregnant and if fertile must use a medically acceptable contraceptive throughout the treatment period.
12. Written informed consent has been given.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>None of the following criteria must apply for the patient to be eligible for the trial.
1. Evidence of active or previous local recurrence or in transit disease; or evidence of nodal metastases or regional disease beyond the lymphadenectomy bed.
2. Evidence of distant metastases on clinical or radiological investigation.
3. Patients with prior cancers, except: those diagnosed more than five years ago with no evidence of disease recurrence within this time and with clinical expectation of recurrence of less than 10 %; and successfully treated basal cell or squamous cell skin carcinoma; and carcinoma in situ of cervix; and multiple primary melanoma. However, any patient with previous invasive breast cancer or prostate cancer is excluded.
Note: Treatment with adjuvant systemic therapy does not exclude participation in the trial. However cytotoxic drugs, other than interferon, should not be delivered during, or in close association with, radiation treatment. Documentation of adjuvant systemic therapy will be required.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Stratified allocation. Factors: Institution, Nodal basin site (parotid or neck, axilla or groin), number of nodes involved depending on site, maximum node diameter (&lt;=4, &gt;4) and extent of extrandoal tissue spread (none, limited, extensive). Simple randomisation by computer.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>20/03/2002</anticipatedstartdate>
    <actualstartdate>20/03/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate>21/09/2007</actualenddate>
    <samplesize>250</samplesize>
    <actualsamplesize>250</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,WA,VIC</recruitmentstate>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>Mater Sydney - North Sydney</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Westmead Private Hospital - Westmead</hospital>
    <hospital>Mater Adult Hospital - South Brisbane</hospital>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Launceston General Hospital - Launceston</hospital>
    <hospital>The Alfred - Prahran </hospital>
    <hospital>Peter MacCallum Cancer Institute - East Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Bryan Burmeister</primarysponsorname>
    <primarysponsoraddress>Princess Alexandra Hospital Oncology Services Ipswich Road Woolloongabba QLD 4102</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Anti-Cancer Council of South Australia</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Trans Tasman Radiation Oncology Group (TROG)</sponsorname>
      <sponsoraddress>Edith St Waratah NSW 2298</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Surgery is the standard treatment for melanoma that has spread to nearby lymph glands, but it sometimes recurs despite surgery.  Radiotherapy given soon after surgery may redue the risk of the melanoma coming back, but mat also cause side effects.  This national randomised trial will determine the benefits and side effects of adding radiotherpay after surgery.</summary>
    <trialwebsite>www.trog.com.au</trialwebsite>
    <publication>Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Kerwin S, Scolyer RA, Curruthjers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson. Adjuvant radiotherapy improves regional lymph node field control in melanoma patients at high risk of relapse after therapeutic lymphadenectomy  results of a randomised intergroup trial. Lancet Oncol 2012, 13 (6): 589  597.

</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>William Buckland Radiotherapy Centre, The Alfred</ethicname>
      <ethicaddress>Prahran, VIC</ethicaddress>
      <ethicapprovaldate>1/08/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Andrew Love Cancer Centre, Geelong Hospital</ethicname>
      <ethicaddress>Geelong, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress>Auckland, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress>Christchurch, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dunedin Hospital</ethicname>
      <ethicaddress>Dunedin, Otago, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Premion Tugun</ethicname>
      <ethicaddress>Tugun, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Groningen University Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Netherlands</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Launceston Hospital</ethicname>
      <ethicaddress>Launceston, TAS</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Hospital</ethicname>
      <ethicaddress>North Sydney, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Calvary Mater Newcastle</ethicname>
      <ethicaddress>Waratah, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress>Melbourne, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress>Wooloongabba, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress>Randwick, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Centre QRI</ethicname>
      <ethicaddress>South Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress>Adelaide, SA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress>Herston, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Perth, WA</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Camperdown, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wellington Hospital</ethicname>
      <ethicaddress>Wellington, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Wentworhville, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Bryan Burmeister</name>
      <address>Princess Alexandra Hospital
Oncology Services
Ipswich Road
Woolloongabba QLD 4102</address>
      <phone>+61 7 3240 6584</phone>
      <fax />
      <email>Bryan_Burmeister@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Juliana Dilulio</name>
      <address>Department of Radiation Oncology
Locked Bag 1
A'Beckett Street
VIC 8006</address>
      <phone>+61 3 9656 3786</phone>
      <fax />
      <email>Juliana.DiIulio@petermac.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>TROG Administrator</name>
      <address>Department of Radiation Oncology Locked Bag 7 Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 4014 3910  </phone>
      <fax>+61 401 43902</fax>
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Bryan Burmeister  </name>
      <address>Princess Alexandra Hospital Oncology Services Ipswich Road Woolloongabba QLD 4102  </address>
      <phone>+61 7 3240 6584  </phone>
      <fax />
      <email>Bryan_Burmeister@health.qld.gov.au  </email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>